Mutations in CHD7, Encoding a Chromatin-Remodeling Protein, Cause Idiopathic Hypogonadotropic Hypogonadism and Kallmann Syndrome
Hyung-Goo Kim,Ingo Kurth,Fei Lan,Irene Meliciani,Wolfgang Wenzel,Soo Hyun Eom,Gil Bu Kang,Georg Rosenberger,Mustafa Tekin,Metin Ozata,David P. Bick,Richard J. Sherins,Steven L. Walker,Yang Shi,James F. Gusella,Lawrence C. Layman
DOI: https://doi.org/10.1016/j.ajhg.2008.09.005
2008-01-01
The American Journal of Human Genetics
Abstract:CHARGE syndrome and Kallmann syndrome (KS) are two distinct developmental disorders sharing overlapping features of impaired olfaction and hypogonadism. KS is a genetically heterogeneous disorder consisting of idiopathic hypogonadotropic hypogonadism (IHH) and anosmia, and is most commonly due to KAL1 or FGFR1 mutations. CHARGE syndrome, a multisystem autosomal-dominant disorder, is caused by CHD7 mutations. We hypothesized that CHD7 would be involved in the pathogenesis of IHH and KS (IHH/KS) without the CHARGE phenotype and that IHH/KS represents a milder allelic variant of CHARGE syndrome. Mutation screening of the 37 protein-coding exons of CHD7 was performed in 101 IHH/KS patients without a CHARGE phenotype. In an additional 96 IHH/KS patients, exons 6–10, encoding the conserved chromodomains, were sequenced. RT-PCR, SIFT, protein-structure analysis, and in situ hybridization were performed for additional supportive evidence. Seven heterozygous mutations, two splice and five missense, which were absent in ≥ 180 controls, were identified in three sporadic KS and four sporadic normosmic IHH patients. Three mutations affect chromodomains critical for proper CHD7 function in chromatin remodeling and transcriptional regulation, whereas the other four affect conserved residues, suggesting that they are deleterious. CHD7's role is further corroborated by specific expression in IHH/KS-relevant tissues and appropriate developmental expression. Sporadic CHD7 mutations occur in 6% of IHH/KS patients. CHD7 represents the first identified chromatin-remodeling protein with a role in human puberty and the second gene to cause both normosmic IHH and KS in humans. Our findings indicate that both normosmic IHH and KS are mild allelic variants of CHARGE syndrome and are caused by CHD7 mutations. CHARGE syndrome and Kallmann syndrome (KS) are two distinct developmental disorders sharing overlapping features of impaired olfaction and hypogonadism. KS is a genetically heterogeneous disorder consisting of idiopathic hypogonadotropic hypogonadism (IHH) and anosmia, and is most commonly due to KAL1 or FGFR1 mutations. CHARGE syndrome, a multisystem autosomal-dominant disorder, is caused by CHD7 mutations. We hypothesized that CHD7 would be involved in the pathogenesis of IHH and KS (IHH/KS) without the CHARGE phenotype and that IHH/KS represents a milder allelic variant of CHARGE syndrome. Mutation screening of the 37 protein-coding exons of CHD7 was performed in 101 IHH/KS patients without a CHARGE phenotype. In an additional 96 IHH/KS patients, exons 6–10, encoding the conserved chromodomains, were sequenced. RT-PCR, SIFT, protein-structure analysis, and in situ hybridization were performed for additional supportive evidence. Seven heterozygous mutations, two splice and five missense, which were absent in ≥ 180 controls, were identified in three sporadic KS and four sporadic normosmic IHH patients. Three mutations affect chromodomains critical for proper CHD7 function in chromatin remodeling and transcriptional regulation, whereas the other four affect conserved residues, suggesting that they are deleterious. CHD7's role is further corroborated by specific expression in IHH/KS-relevant tissues and appropriate developmental expression. Sporadic CHD7 mutations occur in 6% of IHH/KS patients. CHD7 represents the first identified chromatin-remodeling protein with a role in human puberty and the second gene to cause both normosmic IHH and KS in humans. Our findings indicate that both normosmic IHH and KS are mild allelic variants of CHARGE syndrome and are caused by CHD7 mutations. Idiopathic hypogonadotropic hypogonadism (IHH, MIM 146110), one of the most commonly inherited forms of hypogonadism, results from deficient hypothalamic GnRH release or action.1Bhagavath B. Podolsky R.H. Ozata M. Bolu E. Bick D.P. Kulharya A. Sherins R.J. Layman L.C. Clinical and molecular characterization of a large sample of patients with hypogonadotropic hypogonadism.Fertil. Steril. 2006; 85: 706-713Abstract Full Text Full Text PDF PubMed Scopus (91) Google Scholar IHH patients present with absent or impaired sexual development due to sex-steroid-hormone deficiency, low serum levels of the pituitary gonadotropins follicle-stimulating hormone (FSH) and luteinizing hormone (LH), and infertility.1Bhagavath B. Podolsky R.H. Ozata M. Bolu E. Bick D.P. Kulharya A. Sherins R.J. Layman L.C. Clinical and molecular characterization of a large sample of patients with hypogonadotropic hypogonadism.Fertil. Steril. 2006; 85: 706-713Abstract Full Text Full Text PDF PubMed Scopus (91) Google Scholar Kallmann syndrome (KS, MIM 308700, 147950, 244200, 610628), which couples IHH with the inability to smell (anosmia), is due to impairment of the normal embryologic migration of GnRH and olfactory neurons from the olfactory placode region into the hypothalamus.1Bhagavath B. Podolsky R.H. Ozata M. Bolu E. Bick D.P. Kulharya A. Sherins R.J. Layman L.C. Clinical and molecular characterization of a large sample of patients with hypogonadotropic hypogonadism.Fertil. Steril. 2006; 85: 706-713Abstract Full Text Full Text PDF PubMed Scopus (91) Google Scholar, 2Kim H.G. Bhagavath B. Layman L.C. Clinical Manifestations of Impaired GnRH Neuron Development and Function.Neurosignals. 2008; 16: 165-182Crossref PubMed Scopus (41) Google Scholar KS patients may have additional phenotypic abnormalities including cleft lip and palate, unilateral renal agenesis, dental agenesis, and neurologic abnormalities such as synkinesia and cerebellar dysfunction.2Kim H.G. Bhagavath B. Layman L.C. Clinical Manifestations of Impaired GnRH Neuron Development and Function.Neurosignals. 2008; 16: 165-182Crossref PubMed Scopus (41) Google Scholar The molecular basis of IHH and KS (IHH/KS) has been identified for approximately 25%–30% of patients, with mutations in the KAL1 (MIM 308700),3Franco B. Guioli S. Pragliola A. Incerti B. Bardoni B. Tonlorenzi R. Carrozzo R. Maestrini E. Pieretti M. Taillon-Miller P. et al.A gene deleted in Kallmann's syndrome shares homology with neural cell adhesion and axonal path-finding molecules.Nature. 1991; 353: 529-536Crossref PubMed Scopus (726) Google Scholar, 4Legouis R. Hardelin J.P. Levilliers J. Claverie J.M. Compain S. Wunderle V. Millasseau P. Le Paslier D. Cohen D. Caterina D. et al.The candidate gene for the X-linked Kallmann syndrome encodes a protein related to adhesion molecules.Cell. 1991; 67: 423-435Abstract Full Text PDF PubMed Scopus (609) Google Scholar FGFR1 (MIM 136350),5Dode C. Levilliers J. Dupont J.M. De Paepe A. Le Du N. Soussi-Yanicostas N. Coimbra R.S. Delmaghani S. Compain-Nouaille S. Baverel F. et al.Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome.Nat. Genet. 2003; 33: 463-465Crossref PubMed Scopus (604) Google Scholar, 6Kim H.G. Herrick S.R. Lemyre E. Kishikawa S. Salisz J.A. Seminara S. MacDonald M.E. Bruns G.A. Morton C.C. Quade B.J. et al.Hypogonadotropic hypogonadism and cleft lip and palate caused by a balanced translocation producing haploinsufficiency for FGFR1.J. Med. Genet. 2005; 42: 666-672Crossref PubMed Scopus (43) Google Scholar, 7Pitteloud N. Acierno Jr., J.S. Meysing A. Eliseenkova A.V. Ma J. Ibrahimi O.A. Metzger D.L. Hayes F.J. Dwyer A.A. Hughes V.A. et al.Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism.Proc. Natl. Acad. Sci. USA. 2006; 103: 6281-6286Crossref PubMed Scopus (173) Google Scholar and GNRHR (MIM 138850)8de Roux N. Young J. Misrahi M. Genet R. Chanson P. Schaison G. Milgrom E. A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor.N. Engl. J. Med. 1997; 337: 1597-1602Crossref PubMed Scopus (409) Google Scholar, 9Layman L.C. Cohen D.P. Jin M. Xie J. Li Z. Reindollar R.H. Bolbolan S. Bick D.P. Sherins R.J. Duck L.W. et al.Mutations in the gonadotropin-releasing hormone receptor gene cause hypogonadotropic hypogonadism.Nat. Genet. 1998; 18: 14-15Crossref PubMed Scopus (226) Google Scholar genes being most common. A variety of other genes also cause IHH/KS in some patients, including GPR54 (MIM 604161),10Seminara S.B. Messager S. Chatzidaki E.E. Thresher R.R. Acierno Jr., J.S. Shagoury J.K. Bo-Abbas Y. Kuohung W. Schwinof K.M. Hendrick A.G. et al.The GPR54 gene as a regulator of puberty.N. Engl. J. Med. 2003; 349: 1614-1627Crossref PubMed Scopus (1901) Google Scholar NR0B1 (MIM 300473),11Muscatelli F. Strom T.M. Walker A.P. Zanaria E. Recan D. Meindl A. Bardoni B. Guioli S. Zehetner G. Rabl W. et al.Mutations in the DAX-1 gene give rise to both X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism.Nature. 1994; 372: 672-676Crossref PubMed Scopus (599) Google Scholar PROKR2 (MIM 607123),12Dode C. Teixeira L. Levilliers J. Fouveaut C. Bouchard P. Kottler M.L. Lespinasse J. Lienhardt-Roussie A. Mathieu M. Moerman A. et al.Kallmann syndrome: Mutations in the genes encoding prokineticin-2 and prokineticin receptor-2.PLoS Genet. 2006; 2: e175Crossref PubMed Scopus (319) Google Scholar PROK2 (MIM 607002),12Dode C. Teixeira L. Levilliers J. Fouveaut C. Bouchard P. Kottler M.L. Lespinasse J. Lienhardt-Roussie A. Mathieu M. Moerman A. et al.Kallmann syndrome: Mutations in the genes encoding prokineticin-2 and prokineticin receptor-2.PLoS Genet. 2006; 2: e175Crossref PubMed Scopus (319) Google Scholar LEP (MIM 164160),2Kim H.G. Bhagavath B. Layman L.C. Clinical Manifestations of Impaired GnRH Neuron Development and Function.Neurosignals. 2008; 16: 165-182Crossref PubMed Scopus (41) Google Scholar and LEPR (MIM 601007).2Kim H.G. Bhagavath B. Layman L.C. Clinical Manifestations of Impaired GnRH Neuron Development and Function.Neurosignals. 2008; 16: 165-182Crossref PubMed Scopus (41) Google Scholar A digenic inheritance pattern has been reported in two cases.13Pitteloud N. Quinton R. Pearce S. Raivio T. Acierno J. Dwyer A. Plummer L. Hughes V. Seminara S. Cheng Y.Z. et al.Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism.J. Clin. Invest. 2007; 117: 457-463Crossref PubMed Scopus (280) Google Scholar To date, KAL1 mutations cause only KS,2Kim H.G. Bhagavath B. Layman L.C. Clinical Manifestations of Impaired GnRH Neuron Development and Function.Neurosignals. 2008; 16: 165-182Crossref PubMed Scopus (41) Google Scholar whereas GNRHR mutations are restricted to normosmic IHH.14Bhagavath B. Ozata M. Ozdemir I.C. Bolu E. Bick D.P. Sherins R.J. Layman L.C. The prevalence of gonadotropin-releasing hormone receptor mutations in a large cohort of patients with hypogonadotropic hypogonadism.Fertil. Steril. 2005; 84: 951-957Abstract Full Text Full Text PDF PubMed Scopus (47) Google Scholar Only mutations in FGFR1 are known to cause both normosmic IHH and KS. Heterozygous CHD7 (chromodomain helicase DNA-binding protein 7, MIM 608892) mutations have been identified in ∼60%–70% of patients with CHARGE syndrome (MIM 214800), a multisystem autosomal-dominant or sporadic disorder consisting of eye coloboma, heart defects, choanal atresia, retardation of growth and development, genito-urinary anomalies, and ear abnormalities (vestibular and auditory).15Vissers L.E. van Ravenswaaij C.M. Admiraal R. Hurst J.A. de Vries B.B. Janssen I.M. van der Vliet W.A. Huys E.H. de Jong P.J. Hamel B.C. et al.Mutations in a new member of the chromodomain gene family cause CHARGE syndrome.Nat. Genet. 2004; 36: 955-957Crossref PubMed Scopus (869) Google Scholar The large 2997 amino acid (AA) CHD7 protein contains two chromodomains at its N terminus, followed by centrally located SNF2 and helicase domains; three conserved region (CR) domains; a switching-defective protein 3, adaptor 2, nuclear receptor corepressor, transcription factor IIIB (SANT) domain; two Brahma and Kismet (BRK) domains; and, at the C terminus, a leucine-zipper domain, which we identified by using PSORTII prediction software (Figure 1A). The leucine-zipper domain is located in AA 2888–2909 (LAFNPFLLSTMAPGLFYPSMFL). CHD7 belongs to a family of nine CHD proteins that have in common the ability to utilize ATP hydrolysis to alter nucleosome structure.16Marfella C.G. Imbalzano A.N. The Chd family of chromatin remodelers.Mutat. Res. 2007; 618: 30-40Crossref PubMed Scopus (235) Google Scholar Chromodomains have been thought to mediate chromatin interactions and have been found to interact with DNA, RNA, and histone targets.17Brehm A. Tufteland K.R. Aasland R. Becker P.B. The many colours of chromodomains.Bioessays. 2004; 26: 133-140Crossref PubMed Scopus (145) Google Scholar CHD7 is expressed in the disease-associated organs of CHARGE syndrome, but also in KS-relevant tissues including the olfactory epithelium18Bosman E.A. Penn A.C. Ambrose J.C. Kettleborough R. Stemple D.L. Steel K.P. Multiple mutations in mouse Chd7 provide models for CHARGE syndrome.Hum. Mol. Genet. 2005; 14: 3463-3476Crossref PubMed Scopus (149) Google Scholar and pituitary19Hurd E.A. Capers P.L. Blauwkamp M.N. Adams M.E. Raphael Y. Poucher H.K. Martin D.M. Loss of Chd7 function in gene-trapped reporter mice is embryonic lethal and associated with severe defects in multiple developing tissues.Mamm. Genome. 2007; 18: 94-104Crossref PubMed Scopus (106) Google Scholar in mice, as well as the olfactory nerve and bulb, hypothalamus, and pituitary in humans.20Sanlaville D. Etchevers H.C. Gonzales M. Martinovic J. Clement-Ziza M. Delezoide A.L. Aubry M.C. Pelet A. Chemouny S. Cruaud C. et al.Phenotypic spectrum of CHARGE syndrome in fetuses with CHD7 truncating mutations correlates with expression during human development.J. Med. Genet. 2006; 43: 211-217Crossref PubMed Scopus (157) Google Scholar Prior to the identification of CHD7, hypogonadism was reported to be associated with CHARGE syndrome, including some patients old enough to be diagnosed with IHH, as defined below.21Wheeler P.G. Quigley C.A. Sadeghi-Nejad A. Weaver D.D. Hypogonadism and CHARGE association.Am. J. Med. Genet. 2000; 94: 228-231Crossref PubMed Scopus (32) Google Scholar Several other studies implicate a possible connection between the KS phenotype and CHARGE syndrome, although it is important to emphasize that these patients with CHARGE syndrome are not yet of pubertal age. Anosmia or hyposmia has been identified in children with CHARGE syndrome,22Chalouhi C. Faulcon P. Le Bihan C. Hertz-Pannier L. Bonfils P. Abadie V. Olfactory evaluation in children: Application to the CHARGE syndrome.Pediatrics. 2005; 116: e81-e88Crossref PubMed Scopus (72) Google Scholar as well abnormal olfactory bulbs by magnetic resonance imaging (MRI).23Pinto G. Abadie V. Mesnage R. Blustajn J. Cabrol S. Amiel J. Hertz-Pannier L. Bertrand A.M. Lyonnet S. Rappaport R. et al.CHARGE syndrome includes hypogonadotropic hypogonadism and abnormal olfactory bulb development.J. Clin. Endocrinol. Metab. 2005; 90: 5621-5626Crossref PubMed Scopus (112) Google Scholar Most boys studied had micropenis and/or cryptorchidism suggestive of IHH, although all subjects were prepubertal.23Pinto G. Abadie V. Mesnage R. Blustajn J. Cabrol S. Amiel J. Hertz-Pannier L. Bertrand A.M. Lyonnet S. Rappaport R. et al.CHARGE syndrome includes hypogonadotropic hypogonadism and abnormal olfactory bulb development.J. Clin. Endocrinol. Metab. 2005; 90: 5621-5626Crossref PubMed Scopus (112) Google Scholar None of seven females under 12 years of age began puberty spontaneously, and hormonal data suggested that IHH could ensue as they got older.23Pinto G. Abadie V. Mesnage R. Blustajn J. Cabrol S. Amiel J. Hertz-Pannier L. Bertrand A.M. Lyonnet S. Rappaport R. et al.CHARGE syndrome includes hypogonadotropic hypogonadism and abnormal olfactory bulb development.J. Clin. Endocrinol. Metab. 2005; 90: 5621-5626Crossref PubMed Scopus (112) Google Scholar In fact, recently one female with CHARGE syndrome due to a CHD7 mutation and with some features of KS has been reported.24Ogata T. Fujiwara I. Ogawa E. Sato N. Udaka T. Kosaki K. Kallmann syndrome phenotype in a female patient with CHARGE syndrome and CHD7 mutation.Endocr. J. 2006; 53: 741-743Crossref PubMed Scopus (37) Google Scholar However, there has been no systematic evaluation of IHH/KS patients without a diagnosis of CHARGE syndrome for the presence of CHD7 mutations. We hypothesized that IHH/KS could be a milder allelic variant of CHARGE syndrome. We first looked at Chd7 mRNA expression in three different mouse GnRH neuronal cell lines, two migratory (GN11 and NLT)25Radovick S. Wray S. Lee E. Nicols D.K. Nakayama Y. Weintraub B.D. Westphal H. Cutler Jr., G.B. Wondisford F.E. Migratory arrest of gonadotropin-releasing hormone neurons in transgenic mice.Proc. Natl. Acad. Sci. USA. 1991; 88: 3402-3406Crossref PubMed Scopus (189) Google Scholar and one postmigratory (GT1-7).26Mellon P.L. Windle J.J. Goldsmith P.C. Padula C.A. Roberts J.L. Weiner R.I. Immortalization of hypothalamic GnRH neurons by genetically targeted tumorigenesis.Neuron. 1990; 5: 1-10Abstract Full Text PDF PubMed Scopus (871) Google Scholar Chd7-mRNA expression was confirmed by cloning and sequencing of the PCR products (not shown). Next, RT-PCR on RNA extracted from KS-relevant rat tissues demonstrated expression in the olfactory bulb, medial basal hypothalamus, and pituitary (Figure S1 available online). Therefore, we undertook an extensive mutation analysis in IHH/KS patients without clinical features of CHARGE syndrome. IHH was defined as the absence of puberty in females ≥ 17 yr old and in males ≥ 18 yr old with low serum gonadotropins as described previously.1Bhagavath B. Podolsky R.H. Ozata M. Bolu E. Bick D.P. Kulharya A. Sherins R.J. Layman L.C. Clinical and molecular characterization of a large sample of patients with hypogonadotropic hypogonadism.Fertil. Steril. 2006; 85: 706-713Abstract Full Text Full Text PDF PubMed Scopus (91) Google Scholar Males had low serum testosterone (<100 ng/dL, with normal being 300–1100), and females had hypoestrogenic amenorrhea, and remaining pituitary function and CNS imaging by MRI or CT were normal.1Bhagavath B. Podolsky R.H. Ozata M. Bolu E. Bick D.P. Kulharya A. Sherins R.J. Layman L.C. Clinical and molecular characterization of a large sample of patients with hypogonadotropic hypogonadism.Fertil. Steril. 2006; 85: 706-713Abstract Full Text Full Text PDF PubMed Scopus (91) Google Scholar KS was defined as IHH and anosmia or hyposmia, as detailed by the University of Pennsylvania Smell Identification Test when possible or by patient history. This study was approved by the Human Assurance Committee (Medical College of Georgia), and signed written consent was obtained from all participants. Previously, mutation screening was performed in most patients for KAL1, GNRHR, and FGFR1 genes.14Bhagavath B. Ozata M. Ozdemir I.C. Bolu E. Bick D.P. Sherins R.J. Layman L.C. The prevalence of gonadotropin-releasing hormone receptor mutations in a large cohort of patients with hypogonadotropic hypogonadism.Fertil. Steril. 2005; 84: 951-957Abstract Full Text Full Text PDF PubMed Scopus (47) Google Scholar, 27Bhagavath B. Xu N. Ozata M. Rosenfield R.L. Bick D.P. Sherins R.J. Layman L.C. KAL1 mutations are not a common cause of idiopathic hypogonadotrophic hypogonadism in humans.Mol. Hum. Reprod. 2007; 13: 165-170Crossref PubMed Scopus (28) Google Scholar, 28Pedersen-White J.R. Chorich L.P. Bick D.P. Sherins R.J. Layman L.C. The prevalence of intragenic deletions in patients with idiopathic hypogonadotropic hypogonadism and Kallmann syndrome.Mol. Hum. Reprod. 2008; 14: 367-370Crossref PubMed Scopus (49) Google Scholar, 29Xu N. Podolsky R.H. Chudgar P. Chorich L.P. Liu C. McDonough P.G. Warrington J.A. Layman L.C. Screening candidate genes for mutations in patients with hypogonadotropic hypogonadism using custom genome resequencing microarrays.Am. J. Obstet. Gynecol. 2005; 192: 1274-1282Abstract Full Text Full Text PDF PubMed Scopus (12) Google Scholar, 30Xu N. Qin Y. Reindollar R.H. Tho S.P. McDonough P.G. Layman L.C. A mutation in the fibroblast growth factor receptor 1 gene causes fully penetrant normosmic isolated hypogonadotropic hypogonadism.J. Clin. Endocrinol. Metab. 2007; 92: 1155-1158Crossref PubMed Scopus (36) Google Scholar DNA sequencing of the entire 37 protein-coding exons and splice junctions of the CHD7 gene from 101 affected individuals (50 with KS and 51 with normosmic IHH) revealed six heterozygous mutations—one splice-donor site alteration and five missense mutations for a prevalence of 6% (Table 1; Figure 1, Figure 2; Figure S2). Another heterozygous splice-donor site mutation was identified in one of 96 additional IHH/KS patients screened for mutations only in exons 6–10. This gene region was selected for a focused mutation screen because these exons encode the highly conserved and important functional chromodomains (Figure 1). All cases with mutations were sporadic, and none of the probands had any affected family members or relatives. No identical nucleotide changes were identified in 180 controls or listed in the single-nucleotide polymorphism (SNP) database. In addition, the two CHD7 mutations identified in probands of Turkish descent were also absent in 96 Turkish controls. Six new SNPs (Table S1, submitted into the SNP database in NCBI) in the CHD7 were also detected. None of the patients with a CHD7 mutation were known to possess a mutation in another gene involved in IHH/KS.Table 1CHD7 Mutations in Sporadic Patients with IHH/KSPatientGender and PhenotypeGeographic OriginExon or IntronNucleotide ChangeAmino Acid ChangeConfirmatory MethodTT20Male, IHH; no other anomaliesTurkeyIntron 8IVS8+5G→APremature termination0/180 controls & 0/96 Turkish controlsC187Female, KS, cleft lip and palate, hearing lossUSAIntron 6IVS6+5G→C22 amino acid deletionDe novo, 0/180 controls, and 0/96 Turkish controlsC59Male, IHH and cleft lip; cryptorchidismUSAExon 8c.2501C→TSer834Phe0/180 controlsC148Male, KS; no other anomaliesUSAExon 2c.164A→GHis55Arg0/180 controlsT47Male, IHH, myopia; no other anomaliesTurkeyExon 38c.8365G→AAla2789Thr0/180 controls and 0/96 Turkish controlsC137Male, IHH; cryptorchidismUSAExon 38c.8639C→TPro2880Leu0/180 controls and 0/96 Turkish controlsC26Male, KS; no other anomaliesUSAExon 38c.8842A→GLys2948Glu0/180 controls Open table in a new tab Both intronic mutations impaired mRNA splicing in lymphoblasts of affected individuals and are predicted to interfere with protein function. An IVS8+5G→A mutation identified in a normosmic IHH male without any other anomalies resulted in exon 8 skipping, as determined by RT-PCR of CHD7 exons 4–10 from patient and control lymphoblastoid RNA, subsequent subcloning, and DNA sequencing. This mutant introduces 16 aberrant out-of-frame AA residues, causing a frameshift and subsequent premature termination codon at residue 849 located 49 bp downstream of the junction of exons 7 and 9. This results in a CHD7 protein predicted to be truncated more than 70% of the C terminus (Figure 2A). This transcript is not a normal splice variant because it was absent in four control lymphoblastoid cell lines, and nor was the same G→A transition identified in 180 normal controls. Importantly, this mutation removes about half of the first and all of the second chromodomains, as well as other important domains of the protein, thereby predicting a nonfunctional protein. In a KS female with mild sensorineural deafness and cleft lip and palate, a de novo heterozygous intronic transversion, IVS6+5G→C, was identified. The mutation was absent in both parents. For direct examination of whether this variant affects splicing, CHD7 exons 4–9 were similarly analyzed by RT-PCR. In addition to the normally spliced transcript, a transcript with reduced size demonstrated exon 6 skipping not observed in four controls (Figure 2B). This results in an in-frame deletion of 22 of 66 AAs of chromodomain 1. Chromodomains are evolutionarily conserved16Marfella C.G. Imbalzano A.N. The Chd family of chromatin remodelers.Mutat. Res. 2007; 618: 30-40Crossref PubMed Scopus (235) Google Scholar and known to interact with histone tails.31Bannister A.J. Zegerman P. Partridge J.F. Miska E.A. Thomas J.O. Allshire R.C. Kouzarides T. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain.Nature. 2001; 410: 120-124Crossref PubMed Scopus (2059) Google Scholar, 32Flanagan J.F. Mi L.Z. Chruszcz M. Cymborowski M. Clines K.L. Kim Y. Minor W. Rastinejad F. Khorasanizadeh S. Double chromodomains cooperate to recognize the methylated histone H3 tail.Nature. 2005; 438: 1181-1185Crossref PubMed Scopus (397) Google Scholar Interestingly, this mutation has also been reported in a patient with CHARGE syndrome.33Jongmans M.C. Hoefsloot L.H. van der Donk K.P. Admiraal R.J. Magee A. van de Laar I. Hendriks Y. Verheij J.B. Walpole I. Brunner H.G. et al.Familial CHARGE syndrome and the CHD7 gene: A recurrent missense mutation, intrafamilial recurrence and variability.Am. J. Med. Genet. A. 2008; 146A: 43-50Crossref PubMed Scopus (65) Google Scholar The patient with CHARGE syndrome has additional severe phenotypic findings, including the absence of earlobes, triangular concha, vestibular disturbance, autism-spectrum disorder, and mental retardation,33Jongmans M.C. Hoefsloot L.H. van der Donk K.P. Admiraal R.J. Magee A. van de Laar I. Hendriks Y. Verheij J.B. Walpole I. Brunner H.G. et al.Familial CHARGE syndrome and the CHD7 gene: A recurrent missense mutation, intrafamilial recurrence and variability.Am. J. Med. Genet. A. 2008; 146A: 43-50Crossref PubMed Scopus (65) Google Scholar which are absent in our KS patient. The five missense mutations affect highly conserved AA residues when compared with known CHD7 orthologs (Figure 3A). Four of five point mutations were predicted to be deleterious by SIFT34Ng P.C. Henikoff S. SIFT: Predicting amino acid changes that affect protein function.Nucleic Acids Res. 2003; 31: 3812-3814Crossref PubMed Scopus (3483) Google Scholar (Ser834Phe, Lys2948Glu, Pro2880Leu, and His55Arg), whereas Ala2789Thr was tolerated. Ser834Phe, located in DNA-binding chromodomain 1 (UniProtKB/Swiss-Prot entry Q9P2D1; INTERPRO IPR000953),35Mulder N.J. Apweiler R. Attwood T.K. Bairoch A. Bateman A. Binns D. Bradley P. Bork P. Bucher P. Cerutti L. et al.InterPro, progress and status in 2005.Nucleic Acids Res. 2005; 33: D201-D205Crossref PubMed Scopus (420) Google Scholar, 36Wu C.H. Apweiler R. Bairoch A. Natale D.A. Barker W.C. Boeckmann B. Ferro S. Gasteiger E. Huang H. Lopez R. et al.The Universal Protein Resource (UniProt): An expanding universe of protein information.Nucleic Acids Res. 2006; 34: D187-D191Crossref PubMed Scopus (822) Google Scholar a highly conserved sequence motif observed in a variety of animal and plant species, had the highest confidence measure. Further supportive evidence of the deleterious effect of Ser834Phe comes from the report of the same mutation in three patients from a family with a severe CHARGE syndrome phenotype.37Delahaye A. Sznajer Y. Lyonnet S. Elmaleh-Berges M. Delpierre I. Audollent S. Wiener-Vacher S. Mansbach A.L. Amiel J. Baumann C. et al.Familial CHARGE syndrome because of CHD7 mutation: Clinical intra- and interfamilial variability.Clin. Genet. 2007; 72: 112-121Crossref PubMed Scopus (63) Google Scholar Structural models for the relevant domains suggest that Ala2789Thr and Pro2880Leu, located in the spacer sequence between the BRK2 and leucine-zipper regions, as well as Lys2948Glu, are also detrimental. All three AA residues are located in loop regions so that mutations of these residues will most likely affect structural and binding properties of the domains to their interaction partners (Figures 3B1 and 3B2). The local secondary structure of the region around Pro2880 is a random coil, and the Pro2880Leu mutation induces helix formation in this region, predicting its deleterious effect (data not shown). The Ser834 residue is also located in a loop region, coordinating strongly with adjacent residues in the neighboring helix (Tyr881, context PDYV), so Phe834 will therefore strongly affect protein stability (Figure 3B3). The Ala2789T residue is conserved in seven of eight orthologs, and Lys2948 is relatively conserved (Figure 3A). SIFT was also used to characterize the functional significance of a 22 amino acid (ESVDAEGPVVEKIMSSRSVKKQ) in-frame deletion of exon 6 (IVS6+5G→C mutant) by predicting deleterious effects for almost all possible AA substitutions in this region (data not shown). The splice mutant IVS8+5G→A truncates the functional part of the protein starting at AA 810, including the region from AAs 920–1490. The latter is highly homologous to the SWI2/SNF2 chromatin-remodeling domain of eukaryotic Rad54 (PDB code: 1Z3I)38Thoma N.H. Czyzewski B.K. Alexeev A.A. Mazin A.V. Kowalczykowski S.C. Pavletich N.P. Structure of the SWI2/SNF2 chromatin-remodeling domain of eukaryotic Rad54.Nat. Struct. Mol. Biol. 2005; 12: 350-356Crossref PubMed Scopus (151) Google Scholar and therefore an essential DNA-binding domain of the wild-type. Collectively, involvement of the conserved chromodomain by three mutations, two of which have been identified in patients with CHARGE syndrome,33Jongmans M.C. Hoefsloot L.H. van der Donk K.P. Admiraal R.J. Magee A. van de Laar I. Hendriks Y. Verheij J.B. Walpole I. Brunner H.G. et al.Familial CHARGE syndrome and the CHD7 gene: A recurrent missense mutation, intrafamilial recurrence and variability.Am. J. Med. Genet. A. 2008; 146A: 43-50Crossref PubMed Scopus (65) Google Scholar, 37Delahaye A. Sznajer Y. Lyonnet S. Elmaleh-Berges M. Delpierre I. Audollent S. Wiener-Vacher S. Mansbach A.L. Amiel J. Baumann C. et al.Familial CHARGE syndrome because of CHD7 mutation: Clinical intra- and interfamilial variability.Clin. Genet. 2007; 72: 112-121Crossref PubMed Scopus (63) Google Scholar as well as SIFT AA co